Unique Hereditary Angioedema e-Learning Initiative Launched at 29th Congress of the European Academy of Allergy and Clinical Immunology

LONDON, June 9, 2010 - The HAE Awareness Programme was launched today, an online
interactive training programme aimed to increase awareness of Hereditary
Angioedema (HAE). Developed by an Editorial Board of HAE Experts and
supported by an unrestricted educational grant from CSL Behring Ltd,
www.hae-awareness.net was launched at the 29th Congress of the
European Academy of Allergy and Clinical Immunology (EAACI) where delegates
were among the first to trial a demonstration of the educational resource.

HAE is a rare genetic disorder caused by a deficiency of
C1-INH that is characterised by acute attacks of facial, laryngeal,
abdominal, genital or peripheral oedema(1). HAE has a prevalence of
between one in 10,000 and one in 50,000 and, although symptoms begin during
the first decade of life, patients are not typically diagnosed until their
mid-20s.(2,3)

Symptoms of HAE include episodes of oedema, or swelling, in
the hands, feet, the face, the abdomen and/or the larynx. Patients who have
abdominal attacks of HAE can experience episodes of severe pain, diarrhoea,
nausea and vomiting caused by swelling of the intestinal wall.(1) HAE
attacks that involve the face and larynx can result in airway closure,
asphyxiation, and, if untreated, death.(1,4)

The HAE Awareness Programme is accessible at
www.hae-awareness.net and healthcare professionals completing the
training will be able to gain CPD credits recognised by the Royal College of
Physicians. This unique e-learning initiative is designed to improve the
service provision for patients suffering with HAE by sharing best practice
guidelines and education with all front-line clinicians involved in
delivering care, including acute care physicians, anaesthetists,
dermatologists, immunologists and paediatricians. When users register and
select their speciality, they are automatically routed down specific,
tailored educational streams to the content that is deemed the most
appropriate for their speciality.

Dr Hilary Longhurst, Consultant Clinical Immunologist at Barts
and the London NHS Trust, who helped develop the programme, commented: "The
HAE Awareness Programme is designed to increase awareness among physicians
regarding HAE, its diagnosis, treatment and the unmet needs of patients
suffering from the condition. The HAE Awareness Programme should improve the
standards of care for patients and facilitate more prompt and effective
treatment of HAE."

Eddie Owens, General Manager at CSL Behring Ltd, commented:
"The HAE Awareness Programme has been developed by leading HAE physicians
from the UK and aims to provide healthcare professionals with online,
tailored training to address a previously unmet need. We are delighted to be
part of the team who have made the programme possible."

The HAE Awareness Programme will be available online to UK
clinicians from June 2010. Availability will then expand to include the whole
of Europe later in the autumn.

About CSL Behring

CSL Behring is a global leader in the plasma protein
biotherapeutics industry. Passionate about improving the quality of patients'
lives, CSL Behring manufactures and markets a range of plasma-derived and
recombinant products and related services. The company's therapies are used
in the treatment of immune deficiency disorders, hereditary angioedema,
haemophilia, von Willebrand disease and other bleeding disorders. Other
products are used for the prevention of haemolytic diseases in the newborn
and the treatment of burns. The company also operates one of the world's
largest plasma collection networks, CSL Plasma. CSL Behring is a subsidiary
of CSL Limited, a biopharmaceutical company with headquarters in Melbourne,
Australia. For more information, visit www.cslbehring.co.uk.

Notes to editors

    - The initiative has been made possible through sponsorship
      from CSL Behring Ltd

    - EAACI was held at ExCeL in London from 5th to the 9th of
      June 2010 and is considered to be one of the most important events of
      the year for those with an interest in allergy, allergic diseases and
      immunology

———————————

[1] Agostoni A, Aygoren-Pursun E, Binkley KE, et al. Hereditary and
acquired angioedema: problems and progress: proceedings of the third C1
esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol.
2004;114(3 Suppl):S51-S131.

[2] Bouillet L, Longhurst H, Boccon-Gibodi I, et al. Disease expression
in women with hereditary angioedema. Am J Obstet Gynecol. 2008;199(5):484-7.

[3] Zingale LC, Bork K, Farkas H, et al. Poster 1079: The European
register of hereditary Angioedema: experience and preliminary results. J
Allergy Clin Immunol. 2007;119(Suppl 1):S276.

[4] Reid M, Euerle B, Bollinger E. eMedicine specialities: urticaria and
angioedema. 2008. Available at emedicine.medscape.com/article/135208. Last
accessed March 2010.

For further information, source photography or a case study,
contact Rebecca Fancini at Hill & Knowlton on +44-020-7413-3490 or
rebecca.fancini@hillandknowlton.com

A picture accompanying this release is available through the PA
Photowire. It can be downloaded from www.pa-mediapoint.press.net or
viewed at www.mediapoint.press.net or www.prnewswire.co.uk.

For further information, source photography or a case study, contact Rebecca Fancini at Hill & Knowlton on +44-020-7413-3490 or
rebecca.fancini at hillandknowlton.com